FDA Approves Mogamulizumab for CTCL

August 8, 2018 – The FDA has approved mogamulizumab-kpkc for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy. The approval is specifically for patients with mycosis fungoides (MF) or Sézary syndrome (SS), 2 subtypes of CTCL. The FDA based its decision on findings from the phase III MAVORIC study. Results from the study presented at the 2017 ASH Annual Meeting showed that mogamulizumab … (leggi tutto)